Emmanuelle Waubant, MD, PhD
|Title||Professor of Clinical |
|School||UCSF School of Medicine|
|Address||675 Nelson Rising Lane|
San Francisco CA 94117
|Best Doctors in America||2010||Selected one of the "Best Doctors in America"|
|UCSF||2010||Nominated for the Chancellor's Award for the Advancement of Women|
|American Academy of Neurology||2010||Fellow of the American Academy of Neurology|
|UCSF||2010||Nominated for the Outstanding Faculty Mentorship Award|
|UCSF||2008||Nominated for the Outstanding Faculty Mentorship Award|
Dr Waubant trained as a neurologist in Toulouse, France. She continued her training as a neuroimmunology fellow in Dr Stephen Hauser’s UCSF laboratory, focusing on matrix metalloproteinases (MMP) and their tissue inhibitors (TIMP), and their role in migration of lymphocytes through equivalents of the blood-brain barrier. In 1994, Dr Waubant returned to Toulouse to complete her 2-year junior faculty/chief residency in neurology. Dr Waubant later returned as a clinical research fellow at the UCSF MS Center with Dr Donald Goodkin. During that 3-year period, she furthered her in vitro MMP work to the study in the human disease that helped to understand the role of MMP-9 and TIMP-1 in patients with MS and their relationship to disease activity. After completing her research training at the UCSF MS center, Dr Waubant returned to France to lead a clinical research center at Salpetriere Hospital in Paris for 2 years. She returned to the UCSF MS center in September 2001, where she currently directs clinical research. She is also the Nancy Davis Medical Director and coordinates clinical research collaborations between 6 American MS Centers of Excellence. With the support of the National MS Society, she has started a regional pediatric MS clinic at UCSF in January 2006 and has since seen over 250 patients with pediatric MS or related disorders. She is the editor of the first text book on Pediatric MS and related disorders.
Dr Waubant’s specific interests include the translation of promising agents from the bench to the bedside, understanding factors that predict the response to MS therapies, and risk factors for pediatric MS susceptibility and disease modification. Currently, she is the lead investigator for a neuroprotection phase 2 trial of riluzole in early relapsing remitting MS supported by the National MS Society, and is the recipient of a large NIH grant to study risk factors in pediatric MS and their interactions.
Click the "See All" links for more information and interactive visualizations!
Derived automatically from this person's publications.
People in Profiles who have published with this person.
People who share similar concepts with this person.